Page last updated: 2024-12-06

1,2-di(5-amidino-2-benzofuranyl)ethane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,2-di(5-amidino-2-benzofuranyl)ethane is a chemical compound with the following structure:

![Structure of 1,2-di(5-amidino-2-benzofuranyl)ethane](https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?cid=16379852&t=s)

This compound is **not a known, established chemical** with that specific name and structure. It's possible that this compound exists but has not been characterized or named yet. It's also possible that the name is incorrect or a typo.

Here's why we can't find information about this compound:

* **The name is not standard:** The name uses unconventional naming conventions. The amidino group suggests an amino group with an attached amidine functional group. However, the benzofuranyl part refers to a specific heterocyclic ring system.
* **The structure is complex:** The structure involves a complex combination of aromatic rings and functional groups. Finding a specific compound with this exact structure may be difficult without further context or additional information.

**To help you find the information you need, please provide more details:**

* **Where did you encounter this compound name?**
* **What is the research context?** What are you investigating?
* **Are there any synonyms or alternative names for this compound?**
* **Do you have a more specific description of the compound's structure?**

With more information, we can try to identify the compound and its importance in research.

1,2-di(5-amidino-2-benzofuranyl)ethane: preferential inhibitor of bovine factor Xa; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID47978
CHEMBL ID279962
SCHEMBL ID237460
MeSH IDM0089404

Synonyms (16)

Synonym
2-(2-{5-[(e)-amino(imino)methyl]-1-benzofuran-2-yl}ethyl)-1-benzofuran-5-carboximidamide
2-(2-{5-[(z)-amino(imino)methyl]-1-benzofuran-2-yl}ethyl)-1-benzofuran-5-carboximidamide
2-{2-[5-amino(imino)methylbenzo[b]furan-2-yl]ethyl}benzo[b]furan-5-yl-iminomethanamine
bdbm50041220
1,2-bis(5-amidinobenzofuran-2-yl)ethane
1,2-bis(5-amidino-2-benzofuranyl)ethane
5-benzofurancarboximidamide, 2,2'-(1,2-ethanediyl)bis-
2,2'-(1,2-ethanediyl)bis(5-benzofurancarboximidamide)
1,2-di(5-amidino-2-benzofuranyl)ethane
CHEMBL279962 ,
2-[2-(5-carbamimidoyl-1-benzofuran-2-yl)ethyl]-1-benzofuran-5-carboximidamide
66639-67-6
SCHEMBL237460
DTXSID90216794
nsc 266477
icx5609225
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ProthrombinHomo sapiens (human)IC50 (µMol)5.00000.00000.710710.0000AID210658
Prothrombin Bos taurus (cattle)Ki4.17000.00112.06948.3700AID1132851
Coagulation factor XHomo sapiens (human)IC50 (µMol)0.10000.00030.593710.0000AID51480
Coagulation factor XBos taurus (cattle)Ki0.57000.00700.62531.7000AID527404
Glandular kallikreinSus scrofa (pig)Ki9.53002.70007.10339.5300AID1132853
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (36)

Processvia Protein(s)Taxonomy
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
proteolysisProthrombin Bos taurus (cattle)
acute-phase responseProthrombin Bos taurus (cattle)
positive regulation of blood coagulationProthrombin Bos taurus (cattle)
protein polymerizationProthrombin Bos taurus (cattle)
proteolysisCoagulation factor XHomo sapiens (human)
blood coagulationCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationCoagulation factor XHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor XHomo sapiens (human)
proteolysisCoagulation factor XBos taurus (cattle)
blood coagulationCoagulation factor XBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombin Bos taurus (cattle)
calcium ion bindingProthrombin Bos taurus (cattle)
protein bindingProthrombin Bos taurus (cattle)
fibrinogen bindingProthrombin Bos taurus (cattle)
serine-type endopeptidase activityCoagulation factor XHomo sapiens (human)
calcium ion bindingCoagulation factor XHomo sapiens (human)
protein bindingCoagulation factor XHomo sapiens (human)
phospholipid bindingCoagulation factor XHomo sapiens (human)
serine-type endopeptidase activityCoagulation factor XBos taurus (cattle)
calcium ion bindingCoagulation factor XBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
extracellular regionCoagulation factor XHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor XHomo sapiens (human)
Golgi lumenCoagulation factor XHomo sapiens (human)
plasma membraneCoagulation factor XHomo sapiens (human)
external side of plasma membraneCoagulation factor XHomo sapiens (human)
extracellular spaceCoagulation factor XHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1132852Competitive reversible inhibition of bovine trypsin using alpha-N-benzoyl-DL-arginine-p-nitroanilide hydrochloride as substrate after 15 to 30 mins by Michaelis-Menten plot analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases.
AID1132856Anticoagulant activity in human plasma assessed as prolongation of partial thromboplastin time at 10'-4 M incubated for 30 secs (Rvb = 59 +/- 5.4 secs)1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases.
AID303250Selectivity ratio for IC50 of chloroquine-resistant Plasmodium falciparum K1 over Trypanosoma brucei rhodesiense STIB9002007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.
AID580533Antimicrobial activity against Bacillus anthracis Sterne spores by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.
AID1132853Competitive reversible inhibition of porcine pancreatic kallikrein using alpha-N-benzoyl-DL-arginine-p-nitroanilide hydrochloride as substrate after 15 to 180 mins by Michaelis-Menten plot analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases.
AID303248Selectivity index, ratio for IC50 of rat L6 cells to IC50 of chloroquine-resistant Plasmodium falciparum K12007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.
AID527404Inhibition of bovine factor 10a2010Journal of medicinal chemistry, Sep-09, Volume: 53, Issue:17
Factor Xa inhibitors: next-generation antithrombotic agents.
AID1132858Anticoagulant activity in human plasma assessed as prolongation of partial thromboplastin time at 5 x 10'-6 M incubated for 30 secs (Rvb = 59 +/- 5.4 secs)1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases.
AID303245Antimalarial activity against chloroquine-resistant Plasmodium falciparum K12007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.
AID1132851Competitive reversible inhibition of bovine thrombin using alpha-N-benzoyl-DL-arginine-p-nitroanilide hydrochloride as substrate after 15 to 40 mins by Michaelis-Menten plot analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases.
AID303243Cytotoxicity against rat L6 cells2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.
AID51480In vitro evaluation for the concentration needed for inhibiting factor Xa by 50%1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
AID303244Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB9002007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.
AID303249Selectivity index, ratio for IC50 of rat L6 cells to IC50 of Leishmania donovani (MHOM/SD/62/1S-CL2D) axenic amastigotes2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.
AID53470Inhibitory dose against oncornaviral DNA polymerase activity of moloney murine leukemia virus1980Journal of medicinal chemistry, Jul, Volume: 23, Issue:7
Diaryl amidine derivatives as oncornaviral DNA polymerase inhibitors.
AID210658In vitro evaluation for the concentration needed for inhibiting thrombin by 50%1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
AID580534Antimicrobial activity against Bacillus anthracis Sterne vegetative cells by broth microdilution method2009Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10
Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.
AID303247Selectivity index, ratio for IC50 of rat L6 cells to IC50 of Trypanosoma brucei rhodesiense STIB9002007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.
AID303246Antitrypanosomal activity against Leishmania donovani (MHOM/SD/62/1S-CL2D) axenic amastigotes2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.
AID89212In vitro evaluation for the concentration needed to double the Plasma recalcification clotting time1994Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8
Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors.
AID1132857Anticoagulant activity in human plasma assessed as prolongation of partial thromboplastin time at 10'-5 M incubated for 30 secs (Rvb = 59 +/- 5.4 secs)1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (42.86)18.7374
1990's1 (14.29)18.2507
2000's2 (28.57)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.51 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]